Found: 6
Select item for more details and to access through your institution.
RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Using the Bayesian detection of potential risk using inference on blinded safety data (BDRIBS) method to support the decision to refer an event for unblinded evaluation.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 2, p. 372, doi. 10.1002/pst.2175
- By:
- Publication type:
- Article
Value and Implementation of the Aggregate Safety Assessment Plan.
- Published in:
- Pharmaceutical Medicine, 2023, v. 37, n. 3, p. 171, doi. 10.1007/s40290-023-00470-2
- By:
- Publication type:
- Article
Local Vaccine Site Reactions and Contact Allergy to Aluminum.
- Published in:
- Pediatric Dermatology, 2012, v. 29, n. 1, p. 68, doi. 10.1111/j.1525-1470.2011.01541.x
- By:
- Publication type:
- Article
Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.
- Published in:
- American Journal of Clinical Dermatology, 2018, v. 19, n. 3, p. 437, doi. 10.1007/s40257-017-0341-6
- By:
- Publication type:
- Article
Pneumonia With Chest Wall Invasion in a School-Aged Child.
- Published in:
- 2014
- By:
- Publication type:
- Case Study